CORMEDIX INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.395 USD | +1.22% |
|
-1.48% | +42.02% |
| Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
| Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
Financials (USD)
| Sales 2024 * | 25.16M | Sales 2025 * | 81.93M | Capitalization | 293M |
|---|---|---|---|---|---|
| Net income 2024 * | -45M | Net income 2025 * | 6M | EV / Sales 2024 * | 14.3 x |
| Net Debt 2024 * | 67.4M | Net Debt 2025 * | 48.88M | EV / Sales 2025 * | 4.17 x |
| P/E ratio 2024 * |
-7.2
x | P/E ratio 2025 * |
-56.1
x | Employees | 83 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on CorMedix Inc.
More recommendations
More press releases
| 1 day | -2.20% | ||
| 1 week | -2.02% | ||
| Current month | +25.71% | ||
| 1 month | +35.97% | ||
| 3 months | +66.56% | ||
| 6 months | +68.14% | ||
| Current year | +41.76% |
1 week
5.00
6.22
1 month
4.057.00
Current year
2.897.00
1 year
2.577.00
3 years
2.578.94
5 years
2.1618.80
10 years
0.8652.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 48 | 22-03-17 |
Mathew David
DFI | Director of Finance/CFO | 47 | 20-05-10 |
Tushar Mukherjee
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Myron Kaplan
CHM | Chairman | 79 | 16-04-26 |
Steven Lefkowitz
DFI | Director of Finance/CFO | 68 | 11-08-14 |
Alan Dunton
BRD | Director/Board Member | 70 | 19-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 5.36 | +0.56% | 100 655 |
| 24-04-24 | 5.33 | -2.20% | 422,944 |
| 24-04-23 | 5.45 | +3.22% | 572,806 |
| 24-04-22 | 5.28 | 0.00% | 465,594 |
| 24-04-19 | 5.28 | -2.58% | 1,992,172 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.33
USD
Average target price
13
USD
Spread / Average Target
+143.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.76% | 293M | |
| +5.73% | 70.78B | |
| +10.72% | 9.15B | |
| -15.34% | 4.84B | |
| +34.54% | 4.22B | |
| +5.09% | 3.92B | |
| +27.76% | 2.55B | |
| -28.33% | 2.24B | |
| -24.15% | 2.26B | |
| +6.23% | 1.92B |
- Stock Market
- Equities
- CRMD Stock
